Viking Therapeutics (NASDAQ: VKTX) reported a third-quarter 2026 loss of $1.55 per share on Oct. 28, 2026, wider than the analyst estimate of a $1.06 loss. The bigger story is the company's push to show that its obesity drug VK2735 can be dosed less often, or as a pill, to keep weight off. Management argues that a treatment patients can stay on over the long term is what makes the benefits of weight loss last.
Figures are current as of Oct. 29-30, 2026 and cover the quarter ended Sept. 30, 2026, unless noted.
Key facts
- Oct. 28, 2026: Viking reported a Q3 FY2026 loss of $1.55 per share against an estimated loss of $1.06 per share (a $0.49 difference, per FMP). Revenue was $0.00, as the company has no approved product.
- Quarter ended Sept. 30, 2026: Net loss was $183.2M, versus $90.8M in the year-ago quarter. Operating loss was $187.1M, versus $98.6M.
- Sept. 30, 2026: Cash and short-term investments were $959.8M; total debt was $254.7M; shareholders' equity was $588.6M.
- Oct. 29, 2026: The share price was $26.86, up 5.91% on the latest quote. The 52-week range is $23.82 to $43.15, and market cap is $3.42B.
- Next report: Viking's next earnings date is 2027-02-10, with an analyst EPS estimate of a $1.36 loss (approx., per FMP).
The theme: staying on obesity drugs is the hard part
The next competition in obesity drugs is about maintenance: can someone lose weight on a weekly shot, then move to a lower dose, a monthly shot, or a daily pill and keep most of the loss? Viking argues that less frequent dosing, and staying on a single drug rather than switching between agents, may improve adherence. In its maintenance study, subjects switched to placebo regained weight.
Viking's VK2735 is a drug that targets two gut-hormone receptors (GLP-1 and GIP). The company is developing it as both an injection and a tablet. Management argues that having both forms of the same drug, across several dosing schedules, could let patients stay on one medicine from weight loss through long-term upkeep.
What happened
According to its release, Viking spent the quarter on four fronts:
1. Injection Phase 3 trials (VANQUISH). Two late-stage studies of the injectable form continued on track, with completion expected in 2027. Management said first patients should enter the extension period in early 2027. 2. Pill Phase 3 trials (SUNRISE). The company started its late-stage program for the tablet in October, bringing its total to four registration trials (the studies regulators use to decide on approval). 3. Maintenance data. Part 1 of a dosing study looked at injections. The company said participants who moved to every-other-week or monthly dosing kept a high share of their weight loss compared with those switched to placebo. CEO Brian Lian said it "demonstrated an exciting signal that indicates the potential for novel dosing strategies to manage weight loss long term with lower and less frequent dosing regimens." Part 2, testing daily oral and more injection options, has started, with results expected in 2027. 4. A second drug. VK3019, an amylin-type drug, is nearly done with a first-in-human single-dose safety study. A multiple-dose study is planned for Q1 2027.
To pay for this, Viking closed a large stock and convertible-note offering in September. Convertible notes are debt that can later turn into shares. This is why total debt is now $254.7M and cash is $959.8M.
Why the loss grew
Management said research and development spending rose mainly because of more clinical studies, drug manufacturing, stock-based pay, salaries and outside consultants. General and administrative costs also rose, driven by legal and patent work, consultants and stock pay. The company has no revenue, so every dollar of added spending flows straight into a bigger loss.
The five-quarter table below is included because it shows the spending ramp that is the core of this story.
| Quarter ended | Net loss | Operating cash flow | |---|---|---| | Sept. 30, 2025 | $90.8M | outflow of $94.0M | | Dec. 31, 2025 | $157.7M | outflow of $85.3M | | Mar. 31, 2026 | $158.3M | outflow of $114.0M | | June 30, 2026 | $128.0M | outflow of $125.2M | | Sept. 30, 2026 | $183.2M | outflow of $138.2M |
The cash outflow has risen in each of the last three quarters. Capital spending was $0.00 throughout, so free cash flow equals operating cash flow. CFO Greg Zante said cash usage should average "around $100 million per quarter," though some quarters will be higher and some lower. He also said Q3 operating expense and cash usage were "a little higher" than they might be going forward, which contrasts with the $138.2M Q3 outflow. He said general and administrative costs should stay "fairly flat" near term, rising later as the company moves toward commercialization.
Why it matters for investors
Valuation and peers. Viking's trailing P/E (price relative to earnings) is -5.00, negative because it loses money, so it says little. Compared with FMP-listed peers, all with negative trailing P/E ratios:
| Company | Market cap | P/E (trailing 12 months) | |---|---|---| | Viking (VKTX) | $3.42B | -5.00 | | Kailera (KLRA) | $1.66B | -7.29 | | MBX Biosciences (MBX) | $2.67B | -23.09 | | Madrigal (MDGL) | $9.91B | -33.28 | | NewAmsterdam Pharma (NAMS) | $2.36B | -9.24 |
The market is pricing future approval odds, not current results.
Analysts. Of 24 ratings, 1 is strong buy, 22 are buy and 1 is hold, for a consensus of Buy. Analysts' price targets average $82.00, with a median of $87.00, a high of $120.00 and a low of $34.00, all above the $26.86 recent price. Canaccord Genuity (Oct. 20) and Truist Securities (Oct. 7) both kept Buy ratings. These are analysts' views, not ours. Separately, FMP's discounted cash flow model, which values a company on projected future cash, gives $1.03 per share. That model has little to project for a company with no revenue, so treat it with caution.
Stock Expert AI MoonshotScore. Our MoonshotScore V2 for Viking is 43.8, rated Weak. By pillar, relative to its sector: growth 8, momentum 42, quality 34, safety 30 and valuation 37. Growth is the weakest area, which fits a company with no revenue. Safety is also low. FMP's Piotroski score (a 0-9 financial health check) is 1, and its Altman Z-score (a bankruptcy-risk gauge) is 2.30. Cash on hand is the main offset to those readings.
What could go wrong
- Trial results are uncertain. Management declined to predict VANQUISH-1 efficacy at the 78-week mark, saying such predictions are "really, really hard." It also cautioned against comparing its trials with tirzepatide (Eli Lilly's Zepbound ingredient), saying "we always caution against doing something like that" and that the data "will stand on their own."
- Pills are harder to predict. Lian said oral maintenance outcomes are hard to forecast because of the jump in exposures when moving from a weekly injection to a lower daily oral dose. Separately, he said high single-dose variability with the oral route was why the company did not test a weekly oral regimen.
- Early data are limited. The amylin single-dose data are "hard to read a lot into," management said. Reasons for patients leaving trials are hard to interpret, though blinded discontinuation rates were within expectations.
- Labeling is unsettled. Management hopes extension data can support label language on less frequent dosing, but whether those arms go into the first application is "TBD," with a later supplement seen as more likely.
- Spending is running above guidance. The $138.2M Q3 outflow exceeds the roughly $100 million quarterly average management guided to, and the company said Q3 was a little higher than going forward. The September financing added both shares and convertible notes, and the release says the funds provide runway through completion of the ongoing Phase 3 trials.
What to watch next
- Q4 2026: completion of the VK3019 single-dose study.
- Nov. 14-17, 2026: poster presentations at ObesityWeek, plus management appearances at several investor conferences in November and December.
- Early 2027: first patients entering the VANQUISH extension period, and the start of the VK3019 multiple-dose study.
- 2027: Part 2 maintenance results (including oral options) and completion of both VANQUISH trials.
- Feb. 10, 2027: next scheduled earnings report.
Frequently asked questions
Q: Why did Viking Therapeutics report a bigger loss in Q3 2026?
Viking's net loss for the quarter ended Sept. 30, 2026 was $183.2M, wider than the $90.8M a year earlier. Management attributed the increase to higher research and development and general and administrative expenses, pointing to clinical studies, manufacturing, stock-based compensation, salaries and benefits, consultants, and legal and patent services. The company has no product revenue yet.
Q: Does Viking Therapeutics have enough cash to finish its Phase 3 trials?
Viking held $959.8M in cash and short-term investments on Sept. 30, 2026, against total debt of $254.7M. The company said this provides runway through completion of its ongoing Phase 3 obesity trials and supports commercial preparation. Quarterly operating cash outflow reached $138.2M in Q3, but the CFO said usage should average around $100 million per quarter and that Q3 was a little higher than going forward, so the cushion depends on how spending develops.
Q: What is VK2735, and how is it different from Wegovy or Zepbound?
VK2735 is Viking's experimental obesity drug that targets the GLP-1 and GIP receptors, the same pair of hormone pathways as tirzepatide. It is not approved. The company's pitch is a single drug offered as both an injection and a pill, with flexible dosing for long-term maintenance. That remains unproven until the late-stage trials report.
This is educational content, not investment advice. Past performance does not guarantee future results.